Director
Horizon Therapeutics
Dr. Yang Song, Ph.D., is currently Director of clinical pharmacology in Horizon Therapeutics. She earned her Ph.D. from University of Illinois at Chicago in 2011. She joined Chemocentryx in the same year and began to be involved in the discovery and development of TAVNEOS® (avacopan). In 2017, she joined Gilead Sciences, representing DMPK in cross-functional teams and serving as a subject of matter expert for PBPK modeling. She later joined Horizon Therapeutics and worked as clinical pharmacology lead for clinical candidates in multiple therapeutic areas.